Table 4.

Characteristics of GBM patients with IDH1 mutations

IDH1 mutation
Patient IDPatient age (years) * SexRecurrent GBM Secondary GBM Overall survival (years) § NucleotideAmino acidMutation of TP53Mutation of PTEN, RB1, EGFR, or NF1
Br10P 30 F No No 2.2 G395A R132H Yes No
Br11P 32 M No No 4.1 G395A R132H Yes No
Br12P 31 M No No 1.6 G395A R132H Yes No
Br104X 29 F No No 4.0 C394A R132S Yes No
Br106X 36 M No No 3.8 G395A R132H Yes No
Br122X 53 M No No 7.8 G395A R132H No No
Br123X 34 M No Yes 4.9 G395A R132H Yes No
Br237T 26 M No Yes 2.6 G395A R132H Yes No
Br211T 28 F No Yes 0.3 G395A R132H Yes No
Br27P 32 M Yes Yes 1.2 G395A R132H Yes No
Br129X 25 M Yes Yes 3.2 C394A R132S No No
Br29P 42 F Yes Unknown Unknown G395A R132H Yes No
IDH1 mutant patients (n=12) 33.2 67% M 25% 42% 3.8 100% 100% 83% 0%
IDH1 wild-type patients (n=93) 53.3 65% M 16% 1% 1.1 0% 0% 27% 60%
  • * Patient age refers to age at which the sample was obtained.

  • Recurrent GBM designates a GBM which was resected >3 months after a prior diagnosis of GBM.

  • Secondary GBM designates a GBM which was resected > 1 year after a prior diagnosis of a lower grade glioma (WHO I-III).

  • § Overall survival was calculated using date of GBM diagnosis and date of death or last patient contact: Patients Br10P and Br11P were alive at last contact. Median survival for IDH1 mutant patients and IDH1 wild-type patients was calculated using logrank test. Previous pathologic diagnoses in secondary GBM patients were oligodendroglioma (WHO grade II) in Br123X, low grade glioma (WHO grade I-II) in Br237T and Br211T, anaplastic astrocytoma (WHO grade III) in Br27P, and anaplastic oligodendroglioma (WHO grade III) in Br129X. Mean age and median survival are listed for the groups of IDH1-mutated and IDH1-wild-type patients.